ICML / Lugano 2023

• Risk stratification of DLBCL with MVED2 score using integrative host adipose density and metabolic tumor characteristics compared to other indexes

Catherine Thieblemont

• Clonal architecture of relapsed or refractory follicular helper T-cell lymphoma: an ancillary study of the ORACLE trial, a LYSA study

Romain Loyaux

• Prognostic scoring systems for severe CRS and ICANS after autologous anti-CD19 CAR T cells in large B-cell lymphoma: a DESCAR-T registry study form the LYSA

Pierre Sesques

• Radiomics reflecting tumor and host features improves outcome prediction in follicular lymphoma

Louis Rebaud

• Molecular characterization contributes to diagnosis and predicts outcome in primary mediastinal large B-cell lymphomas: a LYSA study

Vincent Camus

• Romidepsin plus CHOP versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: final analysis of the Ro-CHOP trial

Vincent Camus

• Early FDG-PET adapted treatment of limited stage Hodgkin lymphoma (HL): 10y long term follow-up analysis of the randomized Intergroup EORTC/LYSA/FIL H10 trial

Massimo Federico

• Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Final Analysis of ALYCANTE, a Phase 2 LYSA Study

Roch Houot

• Early ctDNA clearance after CAR T-cell infusion predicts outcome in patients with Large B-cell lymphoma : results from ALYCANTE, a phase 2 LYSA study

Marie-Hélène Delfau-Larue

• Very Long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study

Clémentine Sarkozy

• Rituximab and ibrutinib combination is safe and effective in previously untreated splenic and nodal marginal zone lymphomas: planned preliminary subset analysis of the IELSG47/MALIBU phase II study

Catherine Thieblemont

• Identification of an activated /memory B-cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients.

Camille Laurent

• A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Pablo Mozas

• Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non-Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).

Luc Fornecker

• Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis

Amélie Anota

• REALMA: subset of patients with marginal zone lymphomas from the French nationwide REALYSA real-world prospective cohort

Côme Bommier

• Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)

Duc Thang Hoang

• Cell free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study

Nouhoum Sako

• Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials – A LYSA retrospective analysis

Alexandre Willaume

• Tafasitamab lenalidomide in relapsed/refractory large B-cell lymphomas: a multicentric real-world French experience study

Jérôme Paillassa

• Comparison of overall survival of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) adjusting for crossover in second-line (2L) R/R large B-cell lymphoma

Franck Morschhauser

• Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. A DESCAR-T study.

Samuel Vic

• Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.

Sylvain Carras

• Efficacy of anti-PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA

Amira Marouf

• Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study

Cédric Rossi

• KILT: a randomized non-comparative phase II LYSA study of Lacutamab with GemOx versus GemOx in relapsed/refractory Peripheral T-cell Lymphoma

Morgane Cheminant